title: A glypican-3-derived peptide vaccine against hepatocellular carcinoma.
abstract: The results of a Phase I clinical trial in which a glypican-3 (GPC3)-derived peptide was tested in advanced hepatocellular carcinoma patients point to a strong correlation between immunological and clinical responses. This commentary reviews our fundamental studies and clinical trials on the GPC3-derived peptide vaccine.
authors.affiliation: Division of Cancer Immunotherapy; Research Center for Innovative Oncology; National Cancer Center Hospital East; Kashiwa, Japan.
authors.forename: Yu
authors.initials: Y
authors.lastname: Sawada
authors.forename: Mayuko
authors.initials: M
authors.lastname: Sakai
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Kazuya
authors.initials: K
authors.lastname: Ofuji
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Nakatsura